
Celgene’s Otezla approved for NHS use
pharmafile | August 3, 2016 | News story | Research and Development, Sales and Marketing | Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of patients suffering from severe psoriasis.
This decision comes after the organisation previously rejected the drug last year in November. It also came up against resistance from Germany’s cost-effectiveness agency IQWIG last year when it demanded more data to prove that the drug is worth its cost.
After conducting a rapid review in response to a patient access scheme submitted by Celgene, NICE is now recommending the drug as a treatment for severe chronic plaque psoriasis that has not responded to systemic therapy, or systemic therapy is contradicted or not tolerated, on the condition that the company provides it to the NHS at the discounted rate agreed to in the scheme
Analysts predict Otezla will achieve $1.3 billion in sales by 2018. Celgene’s expectations are even more ambitious; through exploring other possible applications for the drug such as rheumatoid arthritis treatment, the company anticipates up to $2 billion peak sales.
Matt Fellows
Related Content

“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …






